APA (7th ed.) Citation

Xiong, Y., Alemseged, F., Cao, Z., Schwamm, L. H., Zhang, S., Parsons, M. W., . . . Zong, L. (2026). Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): A multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial. Lancet, 407(10530), 763. https://doi.org/10.1016/S0140-6736(25)02633-9

Chicago Style (17th ed.) Citation

Xiong, Yunyun, et al. "Tenecteplase Versus Standard Medical Treatment for Basilar Artery Occlusion Within 24 H (TRACE-5): A Multicentre, Prospective, Randomised, Open-label, Blinded-endpoint, Superiority, Phase 3 Trial." Lancet 407, no. 10530 (2026): 763. https://doi.org/10.1016/S0140-6736(25)02633-9.

MLA (9th ed.) Citation

Xiong, Yunyun, et al. "Tenecteplase Versus Standard Medical Treatment for Basilar Artery Occlusion Within 24 H (TRACE-5): A Multicentre, Prospective, Randomised, Open-label, Blinded-endpoint, Superiority, Phase 3 Trial." Lancet, vol. 407, no. 10530, 2026, p. 763, https://doi.org/10.1016/S0140-6736(25)02633-9.